secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0000950170-25-044098
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics ends 2024 with $71.1M cash; advances (Z)-endoxifen for metastatic breast cancer
--------------------------------------------------------------------------------

- Cash and equivalents $71.1M, no debt; operating expenses fell to $27.6M from $31.4M in 2023.
- Strategic pivot to pursue metastatic breast cancer indication for (Z)-endoxifen, citing streamlined regulatory path.
- Phase 2 EVANGELINE trial of (Z)-endoxifen showed Ki-67 ≤10% response rate >85% across doses; amended protocol to compare 40mg + OFS vs exemestane + OFS.
- Phase 2 KARISMA-Endoxifen: 1mg and 2mg doses reduced mammographic breast density by 17.3 and 23.5 percentage points (p<0.01) vs placebo 0.27 pts.
- R&D expenses down 19% to $14.1M; G&A expenses down 4% to $13.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025044098/0000950170-25-044098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025044098/atos-20250325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer